Laurent Mortier
Inserm(FR)Université de Lille(FR)Centre Hospitalier Universitaire de Lille(FR)Centre de Recherche en Cancérologie de Lyon(FR)Hôpital Claude Huriez(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Nonmelanoma Skin Cancer Studies, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research
Most-Cited Works
- → Pembrolizumab versus Ipilimumab in Advanced Melanoma(2015)5,779 cited
- → Nivolumab in Previously Untreated Melanoma without BRAF Mutation(2014)5,312 cited
- → Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib(2014)2,623 cited
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma(2017)1,459 cited
- → Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy(2016)1,305 cited